APA (7th ed.) Citation

Piperno-Neumann, S., Carlino, M. S., Boni, V., Loirat, D., Speetjens, F. M., Park, J. J., . . . Kapiteijn, E. (2023). A phase I trial of LXS196, a protein kinase C (PKC) inhibitor, for metastatic uveal melanoma. British Journal of Cancer, 128(6), 1040. https://doi.org/10.1038/s41416-022-02133-6

Chicago Style (17th ed.) Citation

Piperno-Neumann, S., et al. "A Phase I Trial of LXS196, a Protein Kinase C (PKC) Inhibitor, for Metastatic Uveal Melanoma." British Journal of Cancer 128, no. 6 (2023): 1040. https://doi.org/10.1038/s41416-022-02133-6.

MLA (9th ed.) Citation

Piperno-Neumann, S., et al. "A Phase I Trial of LXS196, a Protein Kinase C (PKC) Inhibitor, for Metastatic Uveal Melanoma." British Journal of Cancer, vol. 128, no. 6, 2023, p. 1040, https://doi.org/10.1038/s41416-022-02133-6.